Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent Biopharma ( (AU:RGT) ) has shared an announcement.
Argent BioPharma has issued 2,557,450 fully paid ordinary shares and confirmed that these were made without a prospectus under the disclosure exemptions of Australia’s Corporations Act. The company stated it remains compliant with its financial reporting and continuous disclosure obligations and that there is no undisclosed information materially affecting investors’ ability to assess its financial position or the rights attached to the new shares, supporting orderly secondary trading of the securities.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing nano-engineered medicines that modulate the nervous and immune systems. Its lead drug candidates, CannEpil and CimetrA, target drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, supported by proprietary delivery platforms designed to enhance blood–brain and alveolar–capillary barrier penetration.
Average Trading Volume: 180,786
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.56M
For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.